Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Analytical science, Drug discovery

Fragment Screening at (Almost) the Speed of Light

My vague awareness, as an undergraduate in my native South Africa, that structural analysis could help create new drugs, was given direction by the offer of PhD research with Tom Blundell, a world-leading figure in X-ray crystallography at Cambridge. However, it didn’t take long to notice that despite the tremendous power of X-ray crystallography, it was hamstrung by inefficiency. The questions I address now in high-throughput crystallography are often as much scientific as engineering challenges: how can we streamline processes and put the right infrastructure in place to fulfill the promise of the technique?

Currently, I have two roles. At Oxford University, I am part of the not-for-profit Structural Genomics Consortium (www.thesgc.org) – a public–private partnership that started off trying to facilitate compound development by solving structures of medically relevant proteins and placing them in the public domain, but has since moved to actively generating probe molecules. There, as head of the protein crystallography group, it’s my job to make sure that my colleagues can do the crystallization and X-ray experiments they need, as efficiently as possible – methodology is my research focus.

Three years ago, I also became head of a beamline at Diamond Light Source, the UK’s synchrotron facility, a few miles south of Oxford. For the uninitiated, a synchrotron is a particle accelerator, speeding up electrons to near-light speeds to generate very bright beams of X-ray, infrared or ultraviolet light. Each beam, up to 10 billion times brighter than our sun, is focused into an experimental station – the beamline. Beamlines around the world support a huge range of disciplines, but researchers in macromolecular crystallography have always been scientifically prominent users.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Frank von Delft

Frank von Delft is a Principal Investigator of the Protein Crystallography group in the Structural Genomics Consortium at the University of Oxford, and Principal Beamline Scientist of beamline I04-1 at Diamond Light Source, UK.

Related Solutions

Research Field Drug discovery

Dental Curing Lights: Clinical Reality

| Contributed by Ocean Optics

Research Field Genetics

Measuring DNA Absorbance with the STS-UV

| Contributed by Ocean Optics

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Most Popular

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register